Lastly, our interesting case of an AITL patient with CH and subsequent development of DLBCL and the sharing of the same TET2 mutation among all three lesions suggest that a subset of DLBCL, possibly the molecular subtype characterized by mutated TET2 (Lacy et al., 2020), may originate from mutated HSC. Here, TET2 is linked to angioimmunoblastic T-cell lymphoma.